Showing 4301-4310 of 8223 results for "".
- Garnier Nutrisse Announces Drew Barrymore as Brand Ambassadorhttps://practicaldermatology.com/news/garnier-nutrisse-announces-drew-barrymore-as-brand-ambassador/2461577/Drew Barrymore is the new brand ambassador for Garnier Nutrisse, an expansion to her current role with the Garnier portfolio. Barrymore's role debuts with a creative campaign highlighting Garnier Nutrisse's new and improved Nourishing Color Crème formula for nourished hai
- Biomarkers May Predict AD Developmenthttps://practicaldermatology.com/news/biomarkers-may-predict-ad-development/2461575/An immune and lipid profile on the surface of the skin of infants may predict the development of atopic dermatitis months before the onset of illness. “The holy grail to deal with atopic dermatitis is to prevent it,” says study author
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Don't Forget Leprosy: Group Marks 150th Anniversary of Dr. Hansen's Discovery of M. lepraehttps://practicaldermatology.com/news/dont-forget-leprosy-group-marks-150th-anniversary-of-dr-hansens-discovery-of-m-leprae/2461573/The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus, M. leprae, in 1873. They plan to hold an
- Exosome Update: Evolve Skincare to Distribute Elevai Skin Care Products in Canadahttps://practicaldermatology.com/news/exosome-update-evolve-skincare-to-distribute-elevai-skin-care-products-in-canada/2461572/Evolve Medical Inc. is the exclusive distributor for Elevai Skincare products in Canada. The Elevai E-Series product range, a pre-and post-procedure skincare system developed with a proprietary stem cell exosome technology, will now be available to dermatologists
- Study: Psoriasis Medicine May Help Treat Alcohol Use Disorderhttps://practicaldermatology.com/news/psoriasis-medicine-may-help-treat-alcohol-use-diisorder/2461571/Apremilast may be an “incredibly promising” treatment for alcohol use disorder, according to a new study in the Journal of Clinical Investigation. On average, the people who took apremi
- Aldeyra Therapeutics Advances Investigational ADX 629 Into Phase 2 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/aldeyra-therapeutics-advances-investigational-adx-629-into-phase-2-trial-for-atopic-dermatitis/2461568/Aldeyra Therapeutics announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑629, an investigational oral RASP modulator, for the treatment of several systemic diseases, including atopic dermatitis. For the atopic dermatitis indication, the mul
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist